Psychedelics Developer Secures $100M In Series A Funding, Will Support MDMA Approval To Treat PTSD - Compass Pathways (NASDAQ:CMPS), ATAI Life Sciences (NASDAQ:ATAI)
A decade after it was founded as a wholly-owned subsidiary of the Multidisciplinary Association for Psychedelic Studies (MAPS), MAPS Pub